AI takes on IBD colonoscopy: could it outsmart a special light?

NCT ID NCT07694362

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

People with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer and need regular colonoscopies to catch early warning signs. This study compares two techniques—narrow-band imaging (a special light) and an artificial intelligence (AI) system—to see which finds more abnormal tissue during these exams. Each participant will have their colon examined twice in one session, once with each method, by different doctors. The goal is to determine whether AI, which is easier to use, can be a reliable alternative for cancer surveillance in IBD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Artificial intelligence (AI) detection system (ENDO-AID CADe) and narrow-band imaging (NBI)
What this could lead to
If AI proves as good as or better than NBI, it could make cancer surveillance colonoscopies easier and more accessible for people with IBD.
What could go wrong
This is a small, single-center study with 60 participants. The AI tool was designed for people without IBD, so it may not perform as well in inflamed bowels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTIFICIAL INTELLIGENCE (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vall d'Hebron University Hospital

    Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.